Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price fell 7% on Wednesday . The stock traded as low as $3.16 and last traded at $3.17, with a volume of 161,562 shares trading hands. The stock had previously closed at $3.41.

Several research firms have recently weighed in on DRNA. Chardan Capital reissued a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, April 14th. Jefferies Group reissued a “buy” rating and set a $19.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Stifel Nicolaus lowered their price target on Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Finally, Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of “Buy” and an average price target of $11.85.

The company’s market capitalization is $65.70 million. The company has a 50 day moving average of $3.27 and a 200-day moving average of $4.46.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Equities research analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.21) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.